Novo Nordisk reported DKK221.28B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Bausch Health Companies USD -802M 1.26B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Novo Nordisk DKK 33.81B 169.25B Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026